| scholarly article | Q13442814 |
| P50 | author | Jill Belch | Q34004167 |
| P2093 | author name string | J P Becquemin | |
| D Clement | |||
| J Golledge | |||
| W R Hiatt | |||
| John Dormandy | |||
| M Lepäntalo | |||
| D Bergqvist | |||
| F Vermassen | |||
| M Cairols | |||
| A Leizorovicz | |||
| I Baumgartner | |||
| C Diehm | |||
| G M Biasi | |||
| E Minar | |||
| L Norgren | |||
| A Jawien | |||
| B Eikelboom | |||
| CASPAR Writing Committee | |||
| L Matyas | |||
| P Stonebridge | |||
| P433 | issue | 4 | |
| P921 | main subject | placebo | Q269829 |
| clopidogrel | Q410237 | ||
| P304 | page(s) | 825-33, 833.e1-2 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | Journal of Vascular Surgery | Q15755733 |
| P1476 | title | Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial | |
| P478 | volume | 52 |
| Q39007236 | 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines |
| Q39007230 | 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines |
| Q57621177 | 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) |
| Q36627535 | A review of the role of anticoagulation in the treatment of peripheral arterial disease |
| Q50248233 | A silver nanocomposite biomaterial for blood-contacting implants. |
| Q24188060 | Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery |
| Q35216396 | Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? |
| Q93379490 | Antiplatelet therapy for peripheral artery disease |
| Q38721851 | Antithrombotic Therapy After Peripheral Vascular Intervention |
| Q24236309 | Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery |
| Q58751103 | Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities |
| Q38715643 | Antithrombotic therapy in peripheral artery disease |
| Q49884240 | Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. |
| Q35752591 | Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q47436100 | Antithrombotic treatment in peripheral artery disease. |
| Q57243374 | Atherothrombosis and the role of antiplatelet therapy |
| Q27015689 | Chapter III: Management of cardiovascular risk factors and medical therapy |
| Q37968759 | Chapter VI: Follow-up after revascularisation |
| Q37625068 | Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery |
| Q47309879 | Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. |
| Q26798134 | Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis |
| Q38841676 | Comparative effectiveness of anticoagulation on midterm infrainguinal bypass graft patency |
| Q27023150 | Comparative effectiveness review of antiplatelet agents in peripheral artery disease |
| Q34786122 | Comparison of graft patency, limb salvage, and antithrombotic therapy between prosthetic and autogenous below-knee bypass for critical limb ischemia |
| Q26995245 | Critical limb ischemia: advanced medical therapy |
| Q37981977 | Current state of diagnosis and management of critical limb ischemia |
| Q38657444 | Current therapies and investigational drugs for peripheral arterial disease |
| Q38239875 | Distal bypasses in patients with diabetes and infrapopliteal disease: technical considerations to achieve success |
| Q91593307 | ESVM Guideline on peripheral arterial disease |
| Q26999848 | Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials |
| Q34028223 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials |
| Q34227383 | Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial |
| Q35283386 | Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis |
| Q36365830 | Impact of antiplatelet treatment on colorectal cancer staging characteristics |
| Q44337285 | In vivo study of a model tissue-engineered small-diameter vascular bypass graft |
| Q50127096 | Inflammation in Vein Graft Disease. |
| Q52717834 | Interventions for lower extremity peripheral artery disease. |
| Q36786241 | Management of Critical Limb Ischemia |
| Q38834990 | Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia |
| Q38116561 | Medical management of critical limb ischaemia: where do we stand today? |
| Q37887771 | Nitric oxide: a guardian for vascular grafts? |
| Q38706266 | Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence |
| Q57460606 | Oral antiplatelet agents in cardiovascular disease |
| Q40323370 | Perioperative clopidogrel is associated with increased bleeding and blood transfusion at the time of lower extremity bypass |
| Q38006459 | Perioperative management of peripheral vascular trauma |
| Q37889106 | Peripheral artery disease. Part 2: medical and endovascular treatment |
| Q38616610 | Peripheral interventions and antiplatelet therapy: Role in current practice |
| Q60924098 | Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial |
| Q37984281 | Preventive aspects in peripheral artery disease |
| Q38012698 | Role and management of coagulation disorders in peripheral arterial disease |
| Q41955689 | SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial |
| Q38012703 | Surveillance after distal revascularization for critical limb ischaemia. |
| Q34576281 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease |
| Q35083475 | VA Vascular Injury Study (VAVIS): VA-DoD extremity injury outcomes collaboration. |
| Q38837879 | Vein graft failure: from pathophysiology to clinical outcomes. |
| Q53974607 | [Antithrombotic therapy after peripheral arterial revascularization]. |
| Q49977922 | [ESC guidelines 2017 on peripheral arterial diseases : Summary of the most important recommendations and innovations]. |
| Q53198003 | [Vascular replacement in abdominal tumor surgery]. |
Search more.